Online citations, reference lists, and bibliographies.
← Back to Search

Prophylactic Long-acting Granulocyte-colony Stimulating Factors (G-CSF) In Gynecologic Malignancies: An Oncologic Expert Statement

E. Petru, C. Singer, S. Polterauer, A. Galid, C. Schauer, J. Klocker, M. Seifert, A. Reinthaller, C. Benedicic, M. Hubalek, L. Hefler, C. Marth, Tonja Scholl-Firon, G. Bogner, Alain-Gustave Zeimet
Published 2015 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
SummaryWe reviewed the status of the use of the prophylactic long-acting granulocyte colony-stimulating factors (G-CSFs) pegfilgrastim and lipegfilgrastim in gynecologic malignancies. Long-acting G-CSFs should not be used in weekly regimens. Filgrastim is not indicated in patients with febrile and/or severe neutropenia after administration of long-acting G-CSF in the same cycle. One study has shown a moderate effect on febrile neutropenia of ciprofloxacin when co-administered with pegfilgrastim. There is broad evidence from meta-analyses that pegfilgrastim effectively reduces severe neutropenia. In parallel, its adverse effects have been studied extensively. All-cause mortality was significantly reduced by pegfilgrastim. The glycopegylated long-acting G-CSF, lipegfilgrastim has demonstrated antineutropenic efficacy similar to that of pegfilgrastimin in one breast cancer study. In another pivitol non-small cell lung cancer study, impaired survival was observed in the lipegfilgrastim group during the first 30 days of study. The European Medicines Agency claimed more profound safety data to be provided for lipegfilgrastim by 2017.ZusammenfassungDer aktuelle Status der prophylaktischen langwirksamen Granulozyten Kolonie-stimulierender Faktoren (G-CSFs) Pegfilgrastim and Lipegfilgrastim bei gynäkologischen Malignomen wurde zusammengefasst. Langwirksame G-CSFs sollten nicht bei wöchentlichen Chemotherapien angewendet werden. Konventionelles Filgrastim ist bei Patienten mit febriler und/oder schwerer Neutropenie nach Anwendung langwirksamer G-CSF im gleichen Zyklus nicht indiziert. Eine Studie hat einen moderaten Effekt der Begleittherapie von Ciprofloxacin zusätzlich zu Pegfilgrastim auf die febrile Neutropenie gezeigt. Es existiert breite Evidenz auf der Basis großer Studien und Metaanalysen, dass Pegfilgrastim die schwere Neutropenie signifikant reduziert. Parallel wurden seine Nebenwirkungen wie Knochenschmerzen im Detail untersucht. Die Gesamtmortalität wird durch Pegfilgrastim signifikant reduziert. Das andere glykopegylierte langwirksame G-CSF, Lipegfilgrastim, hat eine Pegfilgrastim vergleichbare antineutropenische Effektivität in einer Brustkrebsstudie gezeigt. In der anderen Zulassungsstudie beim nichtkleinzelligen Bronchuskarzinom wurde während der ersten 30 Tage der Studie gegenüber Plazebo ein schlechteres Überleben in der Lipegfilgrastimgruppe beobachtet. Die Europäische Medizinagentur fordert daher vertiefte Sicherheitsdaten für Lipegfilgrastim bis 2017.
This paper references
Randomized, dose-escalation study of SD/01 compared with daily filgrastim in patients receiving chemotherapy.
E. Johnston (2000)
Risk of Mortality in Patients with Acute Coronary Syndromes”
2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline.
T. Smith (2006)
Evaluation of reported bone pain in patients (pts) receiving chemotherapy in pegfilgrastim clinical trials.
J. Sierra (2009)
Pegfilgrastim support for full delivery of BEACOPP-14 chemotherapy for patients with high-risk Hodgkin's lymphoma: results of a phase II study.
A. Engert (2006)
Bone pain associated with once-per-cycle pegfilgrastim is similar to daily filgrastim in patients with breast cancer.
E. Kubista (2003)
Pegfilgrastim supports delivery of FEC-100 chemotherapy in elderly patients with high risk breast cancer: a randomized phase 2 trial.
G. Romieu (2007)
A randomized, double-blind, active control, multicenter, dose-finding study of XM22, glycopegfilgrastim, in patients with breast cancer receiving myelosuppressive therapy.
A. Buchner (2011)
Prevention of pegfilgrastim-induced bone pain (PIP): A URCC CCOP randomized, double-blind, placebo-controlled trial of 510 cancer patients.
J. Kirshner (2010)
First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study.
C. Vogel (2005)
Management of febrile neutropaenia: ESMO Clinical Practice Guidelines.
J. Klastersky (2016)
Reported Bone Pain in Patients with Breast Cancer Receiving Taxane-Based Chemotherapy in Clinical Trials of Pegfilgrastim.:
L. Schwartzberg (2009)
Open-label, Randomized Study of Pegfilgrastim vs. Daily Filgrastim as an Adjunct to Chemotherapy in Elderly Patients with Non-Hodgkin's Lymphoma
A. Grigg (2003)
Elderly cancer patients receiving chemotherapy benefit from first-cycle pegfilgrastim.
L. Balducci (2007)
Management of febrile neutropenia: ESMO Clinical Practice Guidelines.
J. de Naurois (2010)
Comparable efficacy and safety profiles of once-per-cycle pegfilgrastim and daily injection filgrastim in chemotherapy-induced neutropenia: a multicenter dose-finding study in women with breast cancer.
F. Holmes (2002)
Lenalidomide, adriamycin, and dexamethasone (RAD) in patients with relapsed and refractory multiple myeloma: a report from the German Myeloma Study Group DSMM (Deutsche Studiengruppe Multiples Myelom).
S. Knop (2009)
Use of pegfilgrastim support on day 9 to maintain relative dose intensity of chemotherapy in breast cancer patients receiving a day 1 and 8 CMF regimen
R. Mattioli (2009)
Risk of mortality in patients with cancer who experience febrile neutropenia
G. Lyman (2010)
Pegfilgrastim for peripheral CD34+ mobilization in patients with solid tumours
F. Willis (2009)
Doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: The European Organization for Research and Treatment of Cancer 10961 Multicenter Phase III Trial.
L. Biganzoli (2002)
Absolute Neutrophil Counts in a Study of Lipegfilgrastim Compared with Pegfilgrastim in Patients with Breast Cancer Who are Receiving Chemotherapy
O. Gladkov (2012)
Efficacy and safety of lipegfilgrastim compared with peg - filgrastim in patients with breast cancer who are receiving chemotherapy
I Bondarenko (2002)
Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741.
M. Citron (2003)
Granulocyte colony-stimulating factors for febrile neutropenia prophylaxis following chemotherapy: systematic review and meta-analysis
K. Cooper (2011)
[Quality of life and cytokines in oncological therapy].
C. Leitgeb (1998)
Balancing the benefits and costs of colony-stimulating factors: a current perspective.
G. Lyman (2003)
Quality of life and cytokines in oncological ther
K Cooper (1998)
Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial.
M. Hensley (2002)
Myeloid growth factors.
J. Crawford (2009)
Efficacy and safety of lipegfilgrastim compared with pegfilgrastim in patients with breast cancer who are receiving chemotherapy.
I. Bondarenko (2012)
Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, phase III trial.
J. Nabholtz (2003)
Fixed-dose Pegfilgrastim is Safe and Allows Neutrophil Recovery in Patients with Non-Hodgkin's Lymphoma
S. George (2003)
Efficacy and safety of balugrastim compared with pegfilgrastim in patients with breast cancer receiving chemotherapy.
C. Volovaț (2014)
Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review.
N. Kuderer (2007)
A single dose of pegfilgrastim compared with daily filgrastim for supporting neutrophil recovery in patients treated for low-to-intermediate risk acute myeloid leukemia: results from a randomized, double-blind, phase 2 trial
J. Sierra (2007)
Neutropenia and anxiety in advanced non-small cell lung cancer (NSCLC) patients: initial report of a randomized controlled trial using pegfilgrastim to reduce neutropenia complications
F. Smith (2005)
Pegfilgrastim on the Same Day Versus Next Day of Chemotherapy in Patients With Breast Cancer, Non-Small-Cell Lung Cancer, Ovarian Cancer, and Non-Hodgkin's Lymphoma: Results of Four Multicenter, Double-Blind, Randomized Phase II Studies.
H. Burris (2010)
Efficacy of pegfilgrastim and darbepoetin alfa as hematopoietic support for dose-dense every-2-week adjuvant breast cancer chemotherapy.
H. Burstein (2005)
Achieving Full-Dose, On-Schedule Administration of ACE Chemotherapy Every 14 Days for the Treatment of Patients with Extensive Small-Cell Lung Cancer
R. Pirker (2005)
Dose-dense R-CHOP-14 supported by pegfilgrastim in patients with diffuse large B-cell lymphoma: a phase II study of feasibility and toxicity.
E. Brusamolino (2006)
Comparison of pegfilgrastim with filgrastim on febrile neutropenia, grade IV neutropenia and bone pain: a meta-analysis of randomized controlled trials
L. Pinto (2007)
A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy.
M. Green (2003)
Pegfilgrastim Supports Delivery of CHOP-R Chemotherapy Administered Every 14 Days: A Randomised Phase II Study.
A. Lopez (2004)
Pegfilgrastim +/- ciprofloxacin for primary prophylaxis with TAC (docetaxel/doxorubicin/cyclophosphamide) chemotherapy for breast cancer. Results from the GEPARTRIO study.
G. von Minckwitz (2008)
A phase 2 pilot study of pegfilgrastim and filgrastim for mobilizing peripheral blood progenitor cells in patients with non-Hodgkin’s lymphoma receiving chemotherapy
N. Russell (2008)
2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours.
M. Aapro (2011)
Austrian Arbeitsgemeinschaft für Gynäkologische Onkologie (AGO) guideline for prophylaxis with granulocyte colony-stimulating factors (G-CSF) in gynecologic malignancies, including breast cancer
E. Petru (2012)
Randomized, multicenter, open-label study of pegfilgrastim compared with daily filgrastim after chemotherapy for lymphoma.
J. Vose (2003)
Colony-stimulating factors for chemotherapy-induced febrile neutropenia: a meta-analysis of randomized controlled trials.
O. Clark (2005)
Phase II, randomized, open-label study of pegfilgrastim-supported VDC/IE chemotherapy in pediatric sarcoma patients.
S. Spunt (2010)
Pegfilgrastim to support CHOP-14 in elderly patients with non-Hodgkin's lymphoma
M. Wolf (2006)
Neutropenic events in community practices reduced by first and subsequent cycle pegfilgrastim use.
H. Ozer (2007)
Hematopoietic growth factors: ESMO Clinical Practice Guidelines for the applications.
J. Crawford (2010)
Multicenter randomized trial comparing sequential with concomitant administration of doxorubicin and docetaxel as first-line treatment of metastatic breast cancer: a Spanish Breast Cancer Research Group (GEICAM-9903) phase III study.
E. Alba (2004)
Reported Bone Pain in Cancer Patients Receiving Chemotherapy in Pegfilgrastim Clinical Trials: A Retrospective Analysis.
S. Gregory (2009)
Pegfilgrastim and darbepoetin alfa as haematopoietic support for adjuvant dose dense doxorubicin + cyclophosphamide-paclitaxel in early stage breast cancer patients – results from the ACCELERATE study
R. Boer (2008)
Cost-effectiveness of adding granulocyte colony-stimulating factor to primary prophylaxis with antibiotics in small-cell lung cancer.
J. Timmer-Bonte (2006)
A randomized, placebo-controlled phase ii study evaluating the reduction of neutropenia and febrile neutropenia in patients with colorectal cancer receiving pegfilgrastim with every-2-week chemotherapy.
J. Hecht (2010)
who experience febrile neutropenia
GH Lyman
Evaluation of reported bone pain in cancer patients receiving chemotherapy in pegf lgrastim clinical trials: a retrospective analysis
S. Gregory (2010)
Acute myeloid leukemia or myelodysplastic syndrome in randomized controlled clinical trials of cancer chemotherapy with granulocyte colony-stimulating factor: a systematic review.
G. Lyman (2010)
Low prevalence of circulating t(11;14)(q13;q32)-positive cells in the peripheral blood of healthy individuals as detected by real-time quantitative PCR.
C. Hirt (2004)

This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar